APO RESEARCH · REPORT
Biodefense
Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.
Product & engineering
Understand the product.
Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.
In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.
Selected research
Industry Research
Biodefense Industry Research Report 2026
Market perspective
Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.
In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.
The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.
Read the full market overview
Report Scope
This report quantifies the global Biodefense market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biodefense.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biodefense Market by Company
Emergent Biosolutions
Hytest
GSK
Sanofi
PharmAthene
Bavarian Nordic
SIGA Technologies
Arbutus Biopharma
DynPort Vaccine
Xoma Corporation
Ichor Medical Systems
Aeolus Pharmaceuticals
Achaogen
Elusys Therapeutics
Dynavax Technologies
Cleveland BioLabs
Soligenix
Alnylam Pharmaceuticals
Biodefense Segment by Type
Anthrax
Smallpox
Botulism
Radiation/Nuclear
Others
Biodefense Segment by Application
US Military Market
US Civilian Market
Non - US Market
Biodefense Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biodefense market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biodefense and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biodefense.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biodefense companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anthrax
- Smallpox
- Botulism
- Radiation/Nuclear
- Others
Applications
- US Military Market
- US Civilian Market
- Non - US Market
Companies covered
- Emergent Biosolutions
- Hytest
- GSK
- Sanofi
- PharmAthene
- Bavarian Nordic
- SIGA Technologies
- Arbutus Biopharma
- DynPort Vaccine
- Xoma Corporation
- Ichor Medical Systems
- Aeolus Pharmaceuticals
- Achaogen
- Elusys Therapeutics
- Dynavax Technologies
- Cleveland BioLabs
- Soligenix
- Alnylam Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biodefense by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Anthrax
- 2.2.3 Smallpox
- 2.2.4 Botulism
- 2.2.5 Radiation/Nuclear
- 2.2.6 Others
- 2.3 Biodefense by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 US Military Market
- 2.3.3 US Civilian Market
- 2.3.4 Non - US Market
- 2.4 Assumptions and Limitations
3 Biodefense Breakdown Data by Type
- 3.1 Global Biodefense Historic Market Size by Type (2021-2026)
- 3.2 Global Biodefense Forecasted Market Size by Type (2027-2032)
4 Biodefense Breakdown Data by Application
- 4.1 Global Biodefense Historic Market Size by Application (2021-2026)
- 4.2 Global Biodefense Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biodefense Market Perspective (2021-2032)
- 5.2 Global Biodefense Growth Trends by Region
- 5.2.1 Global Biodefense Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biodefense Historic Market Size by Region (2021-2026)
- 5.2.3 Biodefense Forecasted Market Size by Region (2027-2032)
- 5.3 Biodefense Market Dynamics
- 5.3.1 Biodefense Industry Trends
- 5.3.2 Biodefense Market Drivers
- 5.3.3 Biodefense Market Challenges
- 5.3.4 Biodefense Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biodefense Players by Revenue
- 6.1.1 Global Top Biodefense Players by Revenue (2021-2026)
- 6.1.2 Global Biodefense Revenue Market Share by Players (2021-2026)
- 6.2 Global Biodefense Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biodefense Head Office and Area Served
- 6.4 Global Biodefense Players, Product Type & Application
- 6.5 Global Biodefense Manufacturers Established Date
- 6.6 Global Biodefense Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biodefense Market Size (2021-2032)
- 7.2 North America Biodefense Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biodefense Market Size by Country (2021-2026)
- 7.4 North America Biodefense Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biodefense Market Size (2021-2032)
- 8.2 Europe Biodefense Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biodefense Market Size by Country (2021-2026)
- 8.4 Europe Biodefense Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biodefense Market Size (2021-2032)
- 9.2 Asia-Pacific Biodefense Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biodefense Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biodefense Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biodefense Market Size (2021-2032)
- 10.2 South America Biodefense Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biodefense Market Size by Country (2021-2026)
- 10.4 South America Biodefense Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biodefense Market Size (2021-2032)
- 11.2 Middle East & Africa Biodefense Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biodefense Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biodefense Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Emergent Biosolutions
- 12.1.1 Emergent Biosolutions Company Information
- 12.1.2 Emergent Biosolutions Business Overview
- 12.1.3 Emergent Biosolutions Revenue in Biodefense Business (2021-2026)
- 12.1.4 Emergent Biosolutions Biodefense Product Portfolio
- 12.1.5 Emergent Biosolutions Recent Developments
- 12.2 Hytest
- 12.2.1 Hytest Company Information
- 12.2.2 Hytest Business Overview
- 12.2.3 Hytest Revenue in Biodefense Business (2021-2026)
- 12.2.4 Hytest Biodefense Product Portfolio
- 12.2.5 Hytest Recent Developments
- 12.3 GSK
- 12.3.1 GSK Company Information
- 12.3.2 GSK Business Overview
- 12.3.3 GSK Revenue in Biodefense Business (2021-2026)
- 12.3.4 GSK Biodefense Product Portfolio
- 12.3.5 GSK Recent Developments
- 12.4 Sanofi
- 12.4.1 Sanofi Company Information
- 12.4.2 Sanofi Business Overview
- 12.4.3 Sanofi Revenue in Biodefense Business (2021-2026)
- 12.4.4 Sanofi Biodefense Product Portfolio
- 12.4.5 Sanofi Recent Developments
- 12.5 PharmAthene
- 12.5.1 PharmAthene Company Information
- 12.5.2 PharmAthene Business Overview
- 12.5.3 PharmAthene Revenue in Biodefense Business (2021-2026)
- 12.5.4 PharmAthene Biodefense Product Portfolio
- 12.5.5 PharmAthene Recent Developments
- 12.6 Bavarian Nordic
- 12.6.1 Bavarian Nordic Company Information
- 12.6.2 Bavarian Nordic Business Overview
- 12.6.3 Bavarian Nordic Revenue in Biodefense Business (2021-2026)
- 12.6.4 Bavarian Nordic Biodefense Product Portfolio
- 12.6.5 Bavarian Nordic Recent Developments
- 12.7 SIGA Technologies
- 12.7.1 SIGA Technologies Company Information
- 12.7.2 SIGA Technologies Business Overview
- 12.7.3 SIGA Technologies Revenue in Biodefense Business (2021-2026)
- 12.7.4 SIGA Technologies Biodefense Product Portfolio
- 12.7.5 SIGA Technologies Recent Developments
- 12.8 Arbutus Biopharma
- 12.8.1 Arbutus Biopharma Company Information
- 12.8.2 Arbutus Biopharma Business Overview
- 12.8.3 Arbutus Biopharma Revenue in Biodefense Business (2021-2026)
- 12.8.4 Arbutus Biopharma Biodefense Product Portfolio
- 12.8.5 Arbutus Biopharma Recent Developments
- 12.9 DynPort Vaccine
- 12.9.1 DynPort Vaccine Company Information
- 12.9.2 DynPort Vaccine Business Overview
- 12.9.3 DynPort Vaccine Revenue in Biodefense Business (2021-2026)
- 12.9.4 DynPort Vaccine Biodefense Product Portfolio
- 12.9.5 DynPort Vaccine Recent Developments
- 12.10 Xoma Corporation
- 12.10.1 Xoma Corporation Company Information
- 12.10.2 Xoma Corporation Business Overview
- 12.10.3 Xoma Corporation Revenue in Biodefense Business (2021-2026)
- 12.10.4 Xoma Corporation Biodefense Product Portfolio
- 12.10.5 Xoma Corporation Recent Developments
- 12.11 Ichor Medical Systems
- 12.11.1 Ichor Medical Systems Company Information
- 12.11.2 Ichor Medical Systems Business Overview
- 12.11.3 Ichor Medical Systems Revenue in Biodefense Business (2021-2026)
- 12.11.4 Ichor Medical Systems Biodefense Product Portfolio
- 12.11.5 Ichor Medical Systems Recent Developments
- 12.12 Aeolus Pharmaceuticals
- 12.12.1 Aeolus Pharmaceuticals Company Information
- 12.12.2 Aeolus Pharmaceuticals Business Overview
- 12.12.3 Aeolus Pharmaceuticals Revenue in Biodefense Business (2021-2026)
- 12.12.4 Aeolus Pharmaceuticals Biodefense Product Portfolio
- 12.12.5 Aeolus Pharmaceuticals Recent Developments
- 12.13 Achaogen
- 12.13.1 Achaogen Company Information
- 12.13.2 Achaogen Business Overview
- 12.13.3 Achaogen Revenue in Biodefense Business (2021-2026)
- 12.13.4 Achaogen Biodefense Product Portfolio
- 12.13.5 Achaogen Recent Developments
- 12.14 Elusys Therapeutics
- 12.14.1 Elusys Therapeutics Company Information
- 12.14.2 Elusys Therapeutics Business Overview
- 12.14.3 Elusys Therapeutics Revenue in Biodefense Business (2021-2026)
- 12.14.4 Elusys Therapeutics Biodefense Product Portfolio
- 12.14.5 Elusys Therapeutics Recent Developments
- 12.15 Dynavax Technologies
- 12.15.1 Dynavax Technologies Company Information
- 12.15.2 Dynavax Technologies Business Overview
- 12.15.3 Dynavax Technologies Revenue in Biodefense Business (2021-2026)
- 12.15.4 Dynavax Technologies Biodefense Product Portfolio
- 12.15.5 Dynavax Technologies Recent Developments
- 12.16 Cleveland BioLabs
- 12.16.1 Cleveland BioLabs Company Information
- 12.16.2 Cleveland BioLabs Business Overview
- 12.16.3 Cleveland BioLabs Revenue in Biodefense Business (2021-2026)
- 12.16.4 Cleveland BioLabs Biodefense Product Portfolio
- 12.16.5 Cleveland BioLabs Recent Developments
- 12.17 Soligenix
- 12.17.1 Soligenix Company Information
- 12.17.2 Soligenix Business Overview
- 12.17.3 Soligenix Revenue in Biodefense Business (2021-2026)
- 12.17.4 Soligenix Biodefense Product Portfolio
- 12.17.5 Soligenix Recent Developments
- 12.18 Alnylam Pharmaceuticals
- 12.18.1 Alnylam Pharmaceuticals Company Information
- 12.18.2 Alnylam Pharmaceuticals Business Overview
- 12.18.3 Alnylam Pharmaceuticals Revenue in Biodefense Business (2021-2026)
- 12.18.4 Alnylam Pharmaceuticals Biodefense Product Portfolio
- 12.18.5 Alnylam Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst